Last reviewed · How we verify
NCT04943016
CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies
Phase 1 trial testing CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed/Refractory B-Cell Malignancies in 12 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 July 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- CD19 Chimeric Antigen Receptor (CAR) T Cells — full drug profile →
Conditions studied
- Relapsed/Refractory B-Cell Malignancies — all drugs for Relapsed/Refractory B-Cell Malignancies →
Sponsor
National Taiwan University Hospital
Who can join
Adults 1 to 65, any sex, with Relapsed/Refractory B-Cell Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cells.
Wang YC, Wu PH, Ting WC, Wang YF, et al · · 2025 · cited 6× · PMID 40593569 · DOI 10.1038/s41467-025-60727-z
Verify or expand the search:
- PubMed search for NCT04943016
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04943016 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 29 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04943016.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing